ATXA secures €2.5m in funding to research new cardiovascular drugs

ATXA secures €2.5m in funding to research new cardiovascular drugs
Professor Therese Kinsella of Ataxa Pharmaceuticals

The company is one of just three Irish companies to secure funding in this latest round

ATXA Therapeutics, a University College Dublin (UCD) life sciences spin-out, which is developing novel therapeutic drugs to treat pulmonary arterial hypertension (PAH), and other related cardiovascular conditions, has secured €2.5 million in funding under the European Union’s Horizon 2020 SME Instrument Programme Phase 2.

The company is one of just three Irish companies to secure funding in this latest round. Only 64 companies from across Europe, out of 1,280 applications, were successful in securing funding in this...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post